169605-45-2

Basic information

• Product Name: (S)-3-{[3-(1-{Benzyloxycarbonylamino-[(Z)-benzyloxycarbonylimino]-methyl}-piperidin-4-ylmethoxy)-isoxazole-5-carbonyl]-amino}-2-butoxycarbonylamino-propionic acid methyl ester
• CAS NO: 169605-45-2
• Molecular Weight: 736.779
• Mol File: 169605-45-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-3-{[3-(1-{Benzyloxycarbonylamino-[(Z)-benzyloxycarbonylimino]-methyl}-piperidin-4-ylmethoxy)-isoxazole-5-carbonyl]-amino}-2-butoxycarbonylamino-propionic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-{[3-(1-{Benzyloxycarbonylamino-[(Z)-benzyloxycarbonylimino]-methyl}-piperidin-4-ylmethoxy)-isoxazole-5-carbonyl]-amino}-2-butoxycarbonylamino-propionic acid methyl ester(169605-45-2)
• EPA Substance Registry System: (S)-3-{[3-(1-{Benzyloxycarbonylamino-[(Z)-benzyloxycarbonylimino]-methyl}-piperidin-4-ylmethoxy)-isoxazole-5-carbonyl]-amino}-2-butoxycarbonylamino-propionic acid methyl ester(169605-45-2)

Safety Data

• Hazardous Substances Data: 169605-45-2(Hazardous Substances Data)

Upstream product

• 169605-42-9 4-[5-((S)-2-Butoxycarbonylamino-2-methoxycarbonyl-ethylcarbamoyl)-isoxazol-3-yloxymethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 169605-40-7 4-(5-Methoxycarbonyl-isoxazol-3-yloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 169605-41-8 4-(5-Carboxy-isoxazol-3-yloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 6457-49-4 4-piperidinemethanol 
• 25508-20-7 N,N'-dibenzyloxycarbonyl-(S)-methyl-isothiourea 

Relevant articles and documents

Synthesis and antiplatelet effects of an isoxazole series of glycoprotein IIb/IIIa antagonists

Despite the excellent in vitro potency of a series of benzamide glycoprotein IIb/IIIa antagonists, which have been reported previously, poor in vivo potency in the inhibition of platelet aggregation was observed when the most potent inhibitor XU057 was dosed intravenously to dogs. In this communication, we report that replacement of the benzamide in XU057 with an isoxazolecarboxamide resulted in significant improvement in in vivo potency. More importantly, the analogue XU065 showed an excellent oral antiplatelet effect in dogs.